Skip to content
2000
image of ACSL4-Mediated Ferroptosis and its Biological Functions and Potential Therapeutic Significance in Liver Diseases

Abstract

As the body's main metabolic organ, the liver performs many crucial functions. Liver diseases such as hepatitis and liver cancer are chronic diseases that can seriously damage health. Currently, effective therapeutic strategies remain limited. In recent years, ferroptosis has become an emerging therapeutic target in the diagnosis and treatment of human diseases. Initially identified in tumor cells linked to neurological disorders, it has recently been acknowledged as a crucial element in the advancement of hepatic ailments. Acyl-CoA synthetase long-chain family member 4 (ACSL4) could be a target for ferroptosis driven by unsaturated fatty acid (FA). More specifically, overexpression of ACSL4 causes reactive oxygen species (ROS) and lipid peroxidation (LPO) products to accumulate, therefore aggravating the course of liver cell ferroptosis. Given that ACSL4 has a complex involvement in liver pathophysiology, its targeted control may represent a novel therapeutic approach for liver illnesses. Even so, more research is required to better understand the molecular mechanisms of ACSL4 and its clinical implications. This article will focus on elucidating the key regulatory molecular mechanisms of ACSL4 in ferroptosis and liver disease progression, aiming to highlight ACSL4 as a potential therapeutic target and provide deep insights into the molecular basis of liver pathology.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128412060250917110113
2025-10-06
2026-02-28

  • From This Site

    /content/journals/cpd/10.2174/0113816128412060250917110113
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Devarbhavi H. Asrani S.K. Arab J.P. Nartey Y.A. Pose E. Kamath P.S. Global burden of liver disease: 2023 update. J. Hepatol. 2023 79 2 516 537 10.1016/j.jhep.2023.03.017 36990226
    [Google Scholar]
  2. Mackowiak B. Fu Y. Maccioni L. Gao B. Alcohol-associated liver disease. J. Clin. Invest. 2024 134 3 e176345 10.1172/JCI176345 38299591
    [Google Scholar]
  3. Israelsen M. Francque S. Tsochatzis E.A. Krag A. Steatotic liver disease. Lancet 2024 404 10464 1761 1778 10.1016/S0140‑6736(24)01811‑7 39488409
    [Google Scholar]
  4. Dixon S.J. Olzmann J.A. The cell biology of ferroptosis. Nat. Rev. Mol. Cell Biol. 2024 25 6 424 442 10.1038/s41580‑024‑00703‑5 38366038
    [Google Scholar]
  5. Mortensen M.S. Ruiz J. Watts J.L. Polyunsaturated fatty acids drive lipid peroxidation during ferroptosis. Cells 2023 12 5 804 10.3390/cells12050804 36899940
    [Google Scholar]
  6. Zhao X. Zhao Z. Li B. ACSL4-mediated lipid rafts prevent membrane rupture and inhibit immunogenic cell death in melanoma. Cell Death Dis. 2024 15 9 695 10.1038/s41419‑024‑07098‑3 39343834
    [Google Scholar]
  7. Wei Z. Hang S. Wiredu Ocansey D.K. Human umbilical cord mesenchymal stem cells derived exosome shuttling mir-129-5p attenuates inflammatory bowel disease by inhibiting ferroptosis. J. Nanobiotechnology 2023 21 1 188 10.1186/s12951‑023‑01951‑x 37303049
    [Google Scholar]
  8. Lin J. Lai Y. Lu F. Wang W. Targeting ACSLs to modulate ferroptosis and cancer immunity. Trends Endocrinol. Metab. 2024 36 7 677 690 10.1016/j.tem.2024.09.003 39424456
    [Google Scholar]
  9. Quan J. Bode A.M. Luo X. ACSL family: The regulatory mechanisms and therapeutic implications in cancer. Eur. J. Pharmacol. 2021 909 174397 10.1016/j.ejphar.2021.174397 34332918
    [Google Scholar]
  10. Xu G. Quan S. Schell J. Mitochondrial ACSS1-K635 acetylation knock-in mice exhibit altered metabolism, cell senescence, and nonalcoholic fatty liver disease. Sci. Adv. 2024 10 20 eadj5942 10.1126/sciadv.adj5942 38758779
    [Google Scholar]
  11. Lopes-Marques M. Cunha I. Reis-Henriques M.A. Santos M.M. Castro L.F.C. Diversity and history of the long-chain acyl-CoA synthetase (Acsl) gene family in vertebrates. BMC Evol. Biol. 2013 13 1 271 10.1186/1471‑2148‑13‑271 24330521
    [Google Scholar]
  12. Doll S. Proneth B. Tyurina Y.Y. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 2017 13 1 91 98 10.1038/nchembio.2239 27842070
    [Google Scholar]
  13. Hou J. Jiang C. Wen X. ACSL4 as a potential target and biomarker for anticancer: From molecular mechanisms to clinical therapeutics. Front. Pharmacol. 2022 13 949863 10.3389/fphar.2022.949863 35910359
    [Google Scholar]
  14. Zha X. Liu X. Wei M. Microbiota-derived lysophosphatidylcholine alleviates Alzheimer’s disease pathology via suppressing ferroptosis. Cell Metab. 2025 37 1 169 186.e9 10.1016/j.cmet.2024.10.006 39510074
    [Google Scholar]
  15. Weigand I. Schreiner J. Röhrig F. Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. Cell Death Dis. 2020 11 3 192 10.1038/s41419‑020‑2385‑4 32184394
    [Google Scholar]
  16. Zhou Q. Meng Y. Li D. Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies. Signal Transduct. Target. Ther. 2024 9 1 55 10.1038/s41392‑024‑01769‑5 38453898
    [Google Scholar]
  17. Li S. Zhang G. Hu J. Tian Y. Fu X. Ferroptosis at the nexus of metabolism and metabolic diseases. Theranostics 2024 14 15 5826 5852 10.7150/thno.100080 39346540
    [Google Scholar]
  18. Gong C. Fu X. Ma Q. Gastrodin: Modulating the xCT/GPX4 and ACSL4/LPCAT3 pathways to inhibit ferroptosis after ischemic stroke. Phytomedicine 2025 136 156331 10.1016/j.phymed.2024.156331 39731833
    [Google Scholar]
  19. Liao Y. Chen Q. Liu L. Amino acid is a major carbon source for hepatic lipogenesis. Cell Metab. 2024 36 11 2437 2448.e8 10.1016/j.cmet.2024.10.001 39461344
    [Google Scholar]
  20. Gensluckner S. Wernly B. Datz C. Aigner E. Iron, oxidative stress, and metabolic dysfunction—Associated steatotic liver disease. Antioxidants 2024 13 2 208 10.3390/antiox13020208 38397806
    [Google Scholar]
  21. Sui Y. Geng X. Wang Z. Zhang J. Yang Y. Meng Z. Targeting the regulation of iron homeostasis as a potential therapeutic strategy for nonalcoholic fatty liver disease. Metabolism 2024 157 155953 10.1016/j.metabol.2024.155953 38885833
    [Google Scholar]
  22. Caputo M. Andersson E. Xia Y. Genetic ablation of STE20-type kinase MST4 does not alleviate diet-induced MASLD susceptibility in mice. Int. J. Mol. Sci. 2024 25 4 2446 10.3390/ijms25042446 38397122
    [Google Scholar]
  23. Ghrayeb A. Finney A.C. Agranovich B. Serine synthesis via reversed SHMT2 activity drives glycine depletion and acetaminophen hepatotoxicity in MASLD. Cell Metab. 2024 36 1 116 129.e7 10.1016/j.cmet.2023.12.013 38171331
    [Google Scholar]
  24. Lin H. Tison K. Du Y. Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. Cancer Cell 2024 42 12 2032 2044.e6 10.1016/j.ccell.2024.10.010 39515327
    [Google Scholar]
  25. Zhang Y.Y. Han Y. Li W.N. Xu R.H. Ju H.Q. Tumor iron homeostasis and immune regulation. Trends Pharmacol. Sci. 2024 45 2 145 156 10.1016/j.tips.2023.12.003 38212195
    [Google Scholar]
  26. Xiao D. Chang W. Ao X. Parkin inhibits iron overload-induced cardiomyocyte ferroptosis by ubiquitinating ACSL4 and modulating PUFA-phospholipids metabolism. Acta Pharm. Sin. B 2025 15 3 1589 1607 10.1016/j.apsb.2024.12.027 40370554
    [Google Scholar]
  27. Co H.K.C. Wu C.C. Lee Y.C. Chen S. Emergence of large-scale cell death through ferroptotic trigger waves. Nature 2024 631 8021 654 662 10.1038/s41586‑024‑07623‑6 38987590
    [Google Scholar]
  28. Zhu G. Chi H. Liu M. Multifunctional “ball-rod” Janus nanoparticles boosting Fenton reaction for ferroptosis therapy of non-small cell lung cancer. J. Colloid Interface Sci. 2022 621 12 23 10.1016/j.jcis.2022.04.021 35447518
    [Google Scholar]
  29. Saimoto Y. Kusakabe D. Morimoto K. Lysosomal lipid peroxidation contributes to ferroptosis induction via lysosomal membrane permeabilization. Nat. Commun. 2025 16 1 3554 10.1038/s41467‑025‑58909‑w 40229298
    [Google Scholar]
  30. Xia C. Peng P. Zhang W. Methionine-SAM metabolism-dependent ubiquinone synthesis is crucial for ROS accumulation in ferroptosis induction. Nat. Commun. 2024 15 1 8971 10.1038/s41467‑024‑53380‑5 39420002
    [Google Scholar]
  31. Liu Y. Liu S. Tomar A. Autoregulatory control of mitochondrial glutathione homeostasis. Science 2023 382 6672 820 828 10.1126/science.adf4154 37917749
    [Google Scholar]
  32. Wang S. Gu J. Bian J. Nesfatin-1 mitigates calcific aortic valve disease via suppressing ferroptosis mediated by GSH/GPX4 and ZIP8/SOD2 axes. Free Radic. Biol. Med. 2024 222 149 164 10.1016/j.freeradbiomed.2024.06.004 38851518
    [Google Scholar]
  33. Bersuker K. Hendricks J.M. Li Z. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 2019 575 7784 688 692 10.1038/s41586‑019‑1705‑2 31634900
    [Google Scholar]
  34. Xu X. Xu X.D. Ma M.Q. The mechanisms of ferroptosis and its role in atherosclerosis. Biomed. Pharmacother. 2024 171 116112 10.1016/j.biopha.2023.116112 38171246
    [Google Scholar]
  35. Yu F-f Zuo J. Wang M. Selenomethionine alleviates T-2 toxin-induced articular chondrocyte ferroptosis via the system Xc-/] GSH/GPX4 axis. Ecotoxicol. Environ. Saf. 2025 290 122130 10.1016/j.ecoenv.2024.117569 39700767
    [Google Scholar]
  36. Li W. Han J. Huang B. SLC25A1 and ACLY maintain cytosolic acetyl-CoA and regulate ferroptosis susceptibility via FSP1 acetylation. EMBO J. 2025 44 6 1641 1662 10.1038/s44318‑025‑00369‑5 39881208
    [Google Scholar]
  37. Aboushousha R. van der Velden J. Hamilton N. Glutaredoxin attenuates glutathione levels via deglutathionylation of Otub1 and subsequent destabilization of system xC. Sci. Adv. 2023 9 37 eadi5192 10.1126/sciadv.adi5192 37703360
    [Google Scholar]
  38. Ma L. Chen C. Zhao C. Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer. Signal Transduct. Target. Ther. 2024 9 1 64 10.1038/s41392‑024‑01772‑w 38453925
    [Google Scholar]
  39. Kim J.W. Lee J.Y. Oh M. Lee E.W. An integrated view of lipid metabolism in ferroptosis revisited via lipidomic analysis. Exp. Mol. Med. 2023 55 8 1620 1631 10.1038/s12276‑023‑01077‑y 37612411
    [Google Scholar]
  40. Zhuo B. Qin C. Deng S. The role of ACSL4 in stroke: Mechanisms and potential therapeutic target. Mol. Cell. Biochem. 2025 480 4 2223 2246 10.1007/s11010‑024‑05150‑6 39496916
    [Google Scholar]
  41. Huang Y. Yang J. Lu T. Shao C. Wan H. Puerarin alleviates cerebral ischemia–reperfusion injury by inhibiting ferroptosis through SLC7A11/GPX4/ACSL4 axis and alleviate pyroptosis through caspase-1/GSDMD axis. Mol. Neurobiol. 2025 62 7 8931 8948 10.1007/s12035‑025‑04798‑5 40056342
    [Google Scholar]
  42. Cui J. Chen Y. Yang Q. Protosappanin A protects DOX‐induced myocardial injury and cardiac dysfunction by targeting ACSL4/FTH1 axis‐dependent ferroptosis. Adv. Sci. 2024 2310227 10.1002/advs.202310227
    [Google Scholar]
  43. Linghu M. Luo X. Zhou X. Covalent inhibition of ACSL4 alleviates ferroptosis-induced acute liver injury. Cell Chem. Biol. 2025 32 7 942 954.e5 10.1016/j.chembiol.2025.06.004 40633537
    [Google Scholar]
  44. Li Y. Ran Q. Duan Q. 7-Dehydrocholesterol dictates ferroptosis sensitivity. Nature 2024 626 7998 411 418 10.1038/s41586‑023‑06983‑9 38297130
    [Google Scholar]
  45. Li C. Wu Y. Chen K. Gp78 deficiency in hepatocytes alleviates hepatic ischemia-reperfusion injury via suppressing ACSL4-mediated ferroptosis. Cell Death Dis. 2023 14 12 810 10.1038/s41419‑023‑06294‑x 38065978
    [Google Scholar]
  46. Lin F. Chen W. Zhou J. Mesenchymal stem cells protect against ferroptosis via exosome-mediated stabilization of SLC7A11 in acute liver injury. Cell Death Dis. 2022 13 3 271 10.1038/s41419‑022‑04708‑w 35347117
    [Google Scholar]
  47. Tao L. Xue Y.F. Sun F.F. MitoQ protects against carbon tetrachloride-induced hepatocyte ferroptosis and acute liver injury by suppressing mtROS-mediated ACSL4 upregulation. Toxicol. Appl. Pharmacol. 2024 486 116914 10.1016/j.taap.2024.116914 38522585
    [Google Scholar]
  48. Jin B.R. Lim C.Y. Kim H.J. Lee M. An H.J. Antioxidant mitoquinone suppresses benign prostatic hyperplasia by regulating the AR–NLRP3 pathway. Redox Biol. 2023 65 102816 10.1016/j.redox.2023.102816 37454529
    [Google Scholar]
  49. Wang R. Halimulati M. Huang X. Ma Y. Li L. Zhang Z. Sulforaphane-driven reprogramming of gut microbiome and metabolome ameliorates the progression of hyperuricemia. J. Adv. Res. 2023 52 19 28 10.1016/j.jare.2022.11.003 36371056
    [Google Scholar]
  50. Zhang Y. Shi C. Zhang D. Zhang L. Wang L. Gong Z. Sulforaphane, an NRF2 agonist, alleviates ferroptosis in acute liver failure by regulating HDAC6 activity. J. Integr. Med. 2023 21 5 464 473 10.1016/j.joim.2023.08.002 37620223
    [Google Scholar]
  51. Wan L. Lin K.T. Rahman M.A. Splicing factor SRSF1 promotes pancreatitis and KRASG12D-mediated pancreatic cancer. Cancer Discov. 2023 13 7 1678 1695 10.1158/2159‑8290.CD‑22‑1013 37098965
    [Google Scholar]
  52. Zou S. Sun H. Peng Y. Mu-opioid receptor alleviated ferroptosis in hepatic ischemia-reperfusion injury via the HIF-1α/ KCNQ1OT1 axis. Am. J. Physiol. Cell Physiol. 2023 324 4 C927 C940 10.1152/ajpcell.00394.2022 36717099
    [Google Scholar]
  53. Li M-M. Shi M-J. Feng C-C. Yu Z-Y. Bai X-F. Lu L. LncRNA KCNQ1OT1 promotes NLRP3 inflammasome activation in Parkinson’s disease by regulating pri-miR-186/mature miR-186/] NLRP3 axis. Biochim. Biophys. Acta Mol. Basis Dis. 2024 1870 8 167454 10.1016/j.bbadis.2024.167454 39122224
    [Google Scholar]
  54. He S.L. Chen Y.L. Chen Q.H. Tian Q. Yi S.J. LncRNA KCNQ1OT1 promotes the metastasis of ovarian cancer by increasing the methylation of EIF2B5 promoter. Mol. Med. 2022 28 1 112 10.1186/s10020‑022‑00521‑5 36100884
    [Google Scholar]
  55. Xu B. Li S. Shi R. Liu H. Multifunctional mesoporous silica nanoparticles for biomedical applications. Signal Transduct. Target. Ther. 2023 8 1 435 10.1038/s41392‑023‑01654‑7 37996406
    [Google Scholar]
  56. Abulikemu A. Zhao X. Xu H. Silica nanoparticles aggravated the metabolic associated fatty liver disease through disturbed amino acid and lipid metabolisms-mediated oxidative stress. Redox Biol. 2023 59 102569 10.1016/j.redox.2022.102569 36512914
    [Google Scholar]
  57. Sun M. Sun Q. Li T. Silica nanoparticles induce liver lipid metabolism disorder via ACSL4-mediated ferroptosis. Environ. Pollut. 2024 359 124590 10.1016/j.envpol.2024.124590 39043312
    [Google Scholar]
  58. Liu S. Gao Z. He W. The gut microbiota metabolite glycochenodeoxycholate activates TFR-ACSL4-mediated ferroptosis to promote the development of environmental toxin–linked MAFLD. Free Radic. Biol. Med. 2022 193 Pt 1 213 226 10.1016/j.freeradbiomed.2022.10.270 36265794
    [Google Scholar]
  59. Yan X. Ma L. Chen X. Ferroptosis promotes valproate-induced liver steatosis in vitro and in vivo. Food Chem. Toxicol. 2024 192 114926 10.1016/j.fct.2024.114926 39147356
    [Google Scholar]
  60. Tu B. Wang Y. Wu Z. DIA-based serum proteomics revealed the protective effect of modified siwu decoction against hypobaric hypoxia. J. Ethnopharmacol. 2024 319 Pt 3 117303 10.1016/j.jep.2023.117303 37827297
    [Google Scholar]
  61. Xue X. Wang L. Wu R. Si-Wu-Tang alleviates metabolic dysfunction-associated fatty liver disease by inhibiting ACSL4-mediated arachidonic acid metabolism and ferroptosis in MCD diet-fed mice. Chin. Med. 2024 19 1 79 10.1186/s13020‑024‑00953‑7 38844978
    [Google Scholar]
  62. Wei S. Qiu T. Wang N. Ferroptosis mediated by the interaction between Mfn2 and IREα promotes arsenic-induced nonalcoholic steatohepatitis. Environ. Res. 2020 188 109824 10.1016/j.envres.2020.109824
    [Google Scholar]
  63. Yepuri G. Ramirez L.M. Theophall G.G. DIAPH1-MFN2 interaction regulates mitochondria-SR/ER contact and modulates ischemic/hypoxic stress. Nat. Commun. 2023 14 1 6900 10.1038/s41467‑023‑42521‑x 37903764
    [Google Scholar]
  64. Gao M. Shen H. Li Q. Gu X. Jia T. Wang Y. Perfluorooctane sulfonate (PFOS) induces apoptosis and autophagy by inhibition of PI3K/AKT/mTOR pathway in human granulosa cell line KGN. Environ. Pollut. 2024 344 123333 10.1016/j.envpol.2024.123333 38211877
    [Google Scholar]
  65. Ren S. Wang J. Dong Z. Perfluorooctane sulfonate induces ferroptosis-dependent non-alcoholic steatohepatitis via autophagy-MCU-caused mitochondrial calcium overload and MCU-ACSL4 interaction. Ecotoxicol. Environ. Saf. 2024 280 116553 10.1016/j.ecoenv.2024.116553 38850699
    [Google Scholar]
  66. Wang S. Friedman S.L. Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH). Sci. Transl. Med. 2023 15 716 eadi0759 10.1126/scitranslmed.adi0759 37792957
    [Google Scholar]
  67. Wang D. Tan Z. Yang J. Perfluorooctane sulfonate promotes atherosclerosis by modulating M1 polarization of macrophages through the NF-κB pathway. Ecotoxicol. Environ. Saf. 2023 249 114384 10.1016/j.ecoenv.2022.114384
    [Google Scholar]
  68. Tao L. Yang X. Ge C. Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH. Cell Metab. 2024 36 10 2190 2206.e5 10.1016/j.cmet.2024.07.013 39142286
    [Google Scholar]
  69. Parola M. Pinzani M. Liver fibrosis in NAFLD/NASH: From pathophysiology towards diagnostic and therapeutic strategies. Mol. Aspects Med. 2024 95 101231 10.1016/j.mam.2023.101231 38056058
    [Google Scholar]
  70. Chen C. Chen J. Wang Y. Ganoderma lucidum polysaccharide inhibits HSC activation and liver fibrosis via targeting inflammation, apoptosis, cell cycle, and ECM-receptor interaction mediated by TGF-β/Smad signaling. Phytomedicine 2023 110 154626 10.1016/j.phymed.2022.154626 36603342
    [Google Scholar]
  71. Zhu Y. Wang A. Zhang S. Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells. J. Adv. Res. 2023 49 159 173 10.1016/j.jare.2022.09.007 36167294
    [Google Scholar]
  72. Liu X. Mi X. Wang Z. Ginsenoside Rg3 promotes regression from hepatic fibrosis through reducing inflammation-mediated autophagy signaling pathway. Cell Death Dis. 2020 11 6 454 10.1038/s41419‑020‑2597‑7 32532964
    [Google Scholar]
  73. Hu Y. Lang Z. Li X. Ginsenoside Rg3 promotes hepatic stellate cell ferroptosis by epigenetically regulating ACSL4 to suppress liver fibrosis progression. Phytomedicine 2024 124 155289 10.1016/j.phymed.2023.155289 38176269
    [Google Scholar]
  74. Gui Y. Dai Y. Wang Y. Taohong Siwu Decoction exerts anticancer effects on breast cancer via regulating MYC, BIRC5, EGF and PIK3R1 revealed by HTS 2 technology. Comput. Struct. Biotechnol. J. 2022 20 3461 3472 10.1016/j.csbj.2022.06.044 35860405
    [Google Scholar]
  75. Kundu A. Gali S. Sharma S. Dendropanoxide alleviates thioacetamide-induced hepatic fibrosis via inhibition of ros production and inflammation in BALB/C mice. Int. J. Biol. Sci. 2023 19 9 2630 2647 10.7150/ijbs.80743 37324954
    [Google Scholar]
  76. Wu J. Gong L. Li Y. Tao-Hong-Si-Wu-Tang improves thioacetamide-induced liver fibrosis by reversing ACSL4-mediated lipid accumulation and promoting mitophagy. J. Ethnopharmacol. 2024 333 118456 10.1016/j.jep.2024.118456 38878839
    [Google Scholar]
  77. Yang K. Wang X. Song C. The role of lipid metabolic reprogramming in tumor microenvironment. Theranostics 2023 13 6 1774 1808 10.7150/thno.82920 37064872
    [Google Scholar]
  78. Jamerson L.E. Bradshaw P.C. The roles of white adipose tissue and liver NADPH in dietary restriction-induced longevity. Antioxidants 2024 13 7 820 10.3390/antiox13070820 39061889
    [Google Scholar]
  79. Torcasio R. Gallo Cantafio M.E. Veneziano C. Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity. J. Transl. Med. 2024 22 1 208 10.1186/s12967‑024‑05013‑0 38413989
    [Google Scholar]
  80. Chen J. Ding C. Chen Y. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway. Cancer Lett. 2021 502 154 165 10.1016/j.canlet.2020.12.019 33340617
    [Google Scholar]
  81. Chen X-P. Yang Z-T. Yang S-X. Li E-M. Xie L. PAK2 as a therapeutic target in cancer: Mechanisms, challenges, and future perspectives. Biochim. Biophys. Acta Rev. Cancer 2025 1880 1 189246 10.1016/j.bbcan.2024.189246 39694422
    [Google Scholar]
  82. Wu M. Sarkar C. Guo B. Regulation of cancer metastasis by PAK2. Int. J. Mol. Sci. 2024 25 24 13443 10.3390/ijms252413443 39769207
    [Google Scholar]
  83. Wu D. Zuo Z. Sun X. Li X. Yin F. Yin W. ACSL4 promotes malignant progression of Hepatocellular carcinoma by targeting PAK2 transcription. Biochem. Pharmacol. 2024 224 116206 10.1016/j.bcp.2024.116206 38615921
    [Google Scholar]
  84. Cheng K. Pan J. Liu Q. Exosomal lncRNA XIST promotes perineural invasion of pancreatic cancer cells via miR-211-5p/] GDNF. Oncogene 2024 43 18 1341 1352 10.1038/s41388‑024‑02994‑6 38454138
    [Google Scholar]
  85. Qin X. Zhang J. Lin Y. Sun X. Zhang J. Cheng Z. Identification of MiR-211-5p as a tumor suppressor by targeting ACSL4 in Hepatocellular Carcinoma. J. Transl. Med. 2020 18 1 326 10.1186/s12967‑020‑02494‑7 32859232
    [Google Scholar]
  86. Ding Z. Pan Y. Shang T. URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers. Nat. Commun. 2023 14 1 6269 10.1038/s41467‑023‑41852‑z 37805657
    [Google Scholar]
  87. Zhong J. He X. Gao X. Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling. Nat. Commun. 2023 14 1 5451 10.1038/s41467‑023‑41061‑8
    [Google Scholar]
  88. Leal A.S. Hung P.Y. Chowdhury A.S. Liby K.T. Retinoid X. Retinoid X. Receptor agonists as selective modulators of the immune system for the treatment of cancer. Pharmacol. Ther. 2023 252 108561 10.1016/j.pharmthera.2023.108561 37952906
    [Google Scholar]
  89. Zhao X. Zhu X. Tao H. Liquidambaric acid inhibits the proliferation of hepatocellular carcinoma cells by targeting PPARα-RXRα to down-regulate fatty acid metabolism. Toxicol. Appl. Pharmacol. 2024 490 117042 10.1016/j.taap.2024.117042
    [Google Scholar]
  90. Lu Y. Chan Y.T. Tan H.Y. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2022 41 1 3 10.1186/s13046‑021‑02208‑x 34980204
    [Google Scholar]
  91. Zhan Y. Huang Q. Deng Z. DNA hypomethylation-mediated upregulation of GADD45B facilitates airway inflammation and epithelial cell senescence in COPD. J. Adv. Res. 2025 68 201 214 10.1016/j.jare.2024.02.005 38342401
    [Google Scholar]
  92. Xia H. Lee K.W. Chen J. Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib. Cell Death Discov. 2017 3 1 17058 10.1038/cddiscovery.2017.58 28900541
    [Google Scholar]
  93. Zhu Y. Hart G.W. Dual-specificity RNA aptamers enable manipulation of target-specific O-GlcNAcylation and unveil functions of O-GlcNAc on β-catenin. Cell 2023 186 2 428 445.e27 10.1016/j.cell.2022.12.016 36626902
    [Google Scholar]
  94. Yang Y. Yan Y. Yin J. O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner. Signal Transduct. Target. Ther. 2023 8 1 63 10.1038/s41392‑023‑01316‑8
    [Google Scholar]
  95. Wang J. Wang Z. Yuan J. Wang J. Shen X. The positive feedback between ACSL4 expression and O-GlcNAcylation contributes to the growth and survival of hepatocellular carcinoma. Aging 2020 12 9 7786 7800 10.18632/aging.103092 32357142
    [Google Scholar]
  96. Shi Y. Kotchetkov I.S. Dobrin A. GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy. Mol. Ther. 2024 32 7 2393 2405 10.1016/j.ymthe.2024.05.006 38720457
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128412060250917110113
Loading
ACSL4-Mediated Ferroptosis and its Biological Functions and Potential Therapeutic Significance in Liver Diseases
Bentham Science Publishers ; https://doi.org/10.2174/0113816128412060250917110113
/content/journals/cpd/10.2174/0113816128412060250917110113
/content/journals/cpd/10.2174/0113816128412060250917110113
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: biomolecular marker ; therapeutic target ; ACSL4 ; liver disease ; diagnosis ; metabolism ; ferroptosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test